Outset Medical Q1 revenue up 6%, gross margin expands to 37.2%, net loss narrows

Outset Medical, Inc.

2025-Q1 EPS reported -$3.66 revenue$29,752,000

Net revenue $29.8M (+6% YoY); recurring Tablo consumables & services $22.7M (+20% YoY).
Gross margin 37.2% (non-GAAP 37.6%), up from 29.2% in Q1 2024; product margin 48.3%.
Net loss $25.8M (-$3.66/share) vs. $39.9M (-$11.77) a year ago; operating cash use down 44%.
Reiterated FY2025 guidance: revenue $115M-$125M, non-GAAP gross margin high-30% range, cash use < $50M.
Tariff exemption confirmed under USMCA and for chronically disabled; no expected impact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.